medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2015, Número 1

<< Anterior Siguiente >>

Dermatología Cosmética, Médica y Quirúrgica 2015; 13 (1)


Revisión de materiales de relleno

Aguilar DA, García GP, Rebollo DN, Segura MG, Ruiz ÁJ

Idioma: Español
Referencias bibliográficas: 85
Paginas: 54-64
Archivo PDF: 157.96 Kb.


RESUMEN

Los materiales de relleno tienen más de un siglo en uso. Durante este período de tiempo se ha aprendido mucho acerca de sus riesgos y aplicaciones. Este artículo aborda las principales características de la mayoría de los rellenos que hay en el mercado, tanto de materiales de relleno temporales como el ácido hialurónico o el colágeno, materiales de relleno semipermanentes como la hidroxiapatitia de calcio, o el ácido poliláctico, y materiales de relleno permanentes como el silicón, hidrogel de poliacrilamida , hidrogel de polialquilimida y microesferas de polimetil-metacrilato


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Klein AW. “Techniques for soft tissue augmentation: an ‘a to z’”. Am J Clin Dermatol 2006; 7(2): 107-120.

  2. Glicenstein J. “The first ‘fillers’, Vaseline and paraffin. From miracle to disaster”. Ann Chir Plast Esthet 2007; 52(2): 157-161.

  3. Rappaport, MJ, Vinnick, C, Zarem, H, “Injectable Silicone: Cause of facial nodules, cellultis, ulceration, and migration”. Aesth Plast Surg 1996; 20(3): 267-276.

  4. Wilke TF. “Late development of granulomas after liquid silicone injections”. Plast and Reconstr Surg 1977; 60(2): 179-188.

  5. Pónyai K, Marschalkó M, Hársing J, Ostorházy E, Kelemen Z, Nyirády P, Várkonyi V, Kárpáti S. “Paraffinoma”. J Dtsch Dermatol Ges 2010; 8(9): 686-688.

  6. Smith KC. “Reversible vs. nonreversible fillers in facial aesthetics: concerns and considerations”. Dermatol Online J. 2008; 14(8): 3.

  7. Sánchez-Carpintero I, Candelas D, Ruiz-Rodríguez R. “Dermal fillers: types, indications, and complications”. Actas Dermosifilogr. 2010; 101(5): 381-393.

  8. American Society of Plastic Surgeons. 2000/2005/2006 National Plastic Surgery Statistics. Cosmetic and Reconstructive Procedure Trends. Arlington Heights, Ill: Department of Public Relations. www.plasticsurgery.org

  9. American Society for Aesthetic Plastic Surgery. Cosmetic Plastic Surgery Research Statistics and Trends for 2001–2006. Available from http:// www.cosmeticplasticsurgerystatistics.com/statistics.html.

  10. Beasley KL, Weiss MA, Weiss R.A. “Hyaluronic acid fillers: a comprehensive review”. Facial Plastic Surg. 2009; 25: 86-94.

  11. Vedamurthy M. “Standard guidelines for the use of dermal fillers”. Indian J Dermatol Venereol Leprol. 2008; 74 Suppl: S23-27.

  12. Beer K. “Dermal Fillers and Combinations of Fillers for Facial Rejuvenation”. Dermatol Clin. 2009;27:427-432.

  13. Goldberg D. “Breakthroughs in US dermal fillers for facial soft-tissue augmentation”. Journal of Cosmetic and Laser Therapy. 2009; 11: 240-247.

  14. Cermelli C, Coughi A, Scuri M. “In vitro evaluation of antiviral and virucidal activity of a high molecular weight hyaluronic acid”. Virol J. 2011; 8: 141.

  15. Monreal J. “Fat Grafting to the Nose: Personal Experience with 36 Patients”. Aesthetic Plast Surg. 2011; 35(5): 916-922.

  16. Dreizen NG, Framm L. “Sudden unilateral visual loss after autologous fat injection into the glabellar area”. Am J Ophthalmol 1989; 107: 85-87.

  17. Hu J, Chen W, Wu Y, Chen K, Luo C, Liang Y, et al. “Middle cerebral artery occlusion following autologous bitemporal fat injection”. Neurol India. 2011; 59(3): 474-475.

  18. Piacquadio D, Jarcho M, Goltz R. “Evaluation of hylan b gel as a soft-tissue augmentation implant material”. J Am Acad Dermato. 1997; 36(4): 544-549.

  19. Bezzola A, Micheels P. Esthéliss, Acide Hyaluronique de Conception Suisse. Premiére Étude Complète des Caractéristiques Physico- Chimiques et Essais Cliniques. J Méd Esth Et Chir Derm 2005; 32: 11-20.

  20. Reed RK, Laurent UB, Fraser JR, Laurent TC. “Removal rate of [34] hyaluronan injected subcutaneously in rabbits”. Am J Physiol 1990; 250: H532-535.

  21. Flynn TC, Sarazin D, Bezzola A, Terrani C, Micheels P. “Comparative Histology of Intradermal Implantation of Mono and Biphasic Hyaluronic Acid Fillers”. Dermatol Surg. 2011; 37(5): 637-643.

  22. Klein A. “Soft tissue Augmentation 2006: filler fantasy”. Dermatologic Therapy 2006; 19: 129-133.

  23. Paris P, Micheels P. “L’acide hyaluronique injectable, miracleou revolution?” J Med Esthet Chir Dermatol 1997; 24: 143-148.

  24. Tezel A., Fredrickson G. “The science of hyaluronic acid dermal fillers”. Journal of Cosmetic and Laser Therapy 2008; 10: 35-42.

  25. Wang F, Garza L, Kang S, Varani J, Orringer JS, Fisher GJ, et al. “In vivo stimulation of de novo collagen production caused by cross-linked hyaluronic acid dermal filler injections in photodamaged human skin”. Arch Dermatol 2007; 143: 155-163.

  26. Biesman B. “Soft tissue augmentation using Restylane”. Facial Plast Surg 2004; 20: 171-177.

  27. Wesley NO, Dover JS. “The filler revolution: a six-year retrospective”. J Drugs Dermatol 2009; 8(10): 903-907.

  28. Weinkle SH, Bank DE, Boyd CM, Gold MH, Thomas JA, Murphy DK. “A multi-center, double-blind, randomized controlled study of the safety and effectiveness of Juvéderm injectable gel with and without lidocaine”. J Cosmet Dermatol 2009; 8(3): 205-210.

  29. Medicis Global Services Corporation (clinical trial). “Safety study that compares Restylane to Restylane with Lidocaine while correcting wrinkles in the nasolabial folds”. 2009. On ClinicalTrials.gov

  30. Smith L, Cockerham K. “Hyaluronic acid dermal fillers: can adjunctive lidocaine improve patient satisfaction without decreasing efficacy or duration?” Patient Prefer Adherence 2011; 14(5): 133-139.

  31. Smith SR, Jones D. Thomas JA, Murphy DK, Beddingfield FC 3rd. “Duration of wrinkle correction following repeat treatment with Juvéderm hyaluronic acid fillers”. Arch Dermatol Res. 2010; 302(10): 757-762.

  32. Andre P, Lowe N, Parc A, Clerici T, Zimmermann U. “Adverse reactions to dermal fillers: a review of European experiences”. J Cosmet Laser Ther 2005; 7: 171-176.

  33. Friedman PM, Mafong EA, Kauvar ANB, Geronemus RG. “Safety data of injectable nonanimal stabilized hyaluronic acid gel for soft tissue augmentation”. Dermatol Surg 2002; 28(6): 491-494.

  34. Bachmann F, Erdmann R, Hartmann V, Wiest L, Rzany B. “The spectrum of adverse reactions after treatment with injectable filler in the glabellar region: results from the injectable filler safety study”. Dermatol Surg 2009; 35: 1629-1634.

  35. Odunze M. Cohn A, Few JW. “Restylane and people of color”. Plast Reconstr Surg 2007; 120(7): 2011-2016.

  36. Monheit G, Baumann L, Gold M, Goldberg D, Goldman M, Narins R, et al. “Novel Hyaluronic Acid Dermal Filler: Dermal Gel Extra Physical Properties and Clinical Outcome”. Dermatol Surg 2010; 36: 1833-1841.

  37. Piacquadio D. “Crosslinked hyaluronic acid (hylan gel) as a soft tissue augmentation material: a preliminary assessment”. En: Elson ML, editor. Evaluation and treatment of the aging face. New York (NY): Springer- Verlag, 1994: 304-308.

  38. Andre P. “Evaluation of the safety of a non-animal stabilized hyaluronic acid (NASHA–Q-Medical, Sweden) in European countries: a retrospective study from 1997 to 2001”. J Eur Acad Dermatol Venereol 2004; 18: 422-425.

  39. Arsiwala SZ. “Safety and persistence of non-animal stabilized hyaluronic acid fillers for nasolabial folds correction in 30 indian patients”. J Cutan Aesthet Surg 2010; 3(3): 156-161.

  40. Van Dyke S, Hays GP, Caglia AE, Caglia M. “Severe Acute Local reactions to a Hyaluronic Acid-derived Dermal Filler”. J Clin Aesthet Dermatol 2010; 3(5): 32-35.

  41. Cockerham K, Hsu VJ. “Collagen-based dermal fillers: past, present, future”. Facial Plast Surg 2009; 25(2): 106-113.

  42. Braun M, Braun S. “Nodule formation following lip augmentation using porcine collagen-derived filler”. J Drugs Dermatol 2008; 7(6): 579-581.

  43. Sage RJ, Lopiccolo MC, Liu A, Mahmound BH, Tierney EP, Kouba DJ. “Subcuticular incision versus naturally sourced porcine collagen filler for acne scars: a randomized split-face comparison”. Dermatol Surg 2011; 37(4): 426-431.

  44. Goldberg DJ. “Correction of tear trough deformity with novel porcine collagen dermal filler (Dermicol-P35)”. Aesthet Surg J 2009; 29(3 Suppl): S9-S11.

  45. Narins RS, Brandt FS, Lorenc ZP, Maas CS, Monheit GD, Smith SR. “Twelve-month persistency of a novel ribose-cross-linked collagen dermal filler”. Dermatol Surg 2008; 34 Suppl 1: S31-S39.

  46. Lorenc ZP, Nir E, Azachi M. “Characterization of physical properties and histologic evaluation of injectable Dermicol-p35 porcine-collagen dermal filler”. Plast Reconstr Surg 2010; 125(6): 1805-1813.

  47. Tagle JM. Macchetto PC, Durán Páramo RM. “Clinical performance of a dermal filler containing natural glycolic Acid polymer results of a clinical trial in human immunodeficiency virus subjects with facial lipoatrophy”. J Clin Aesthet Dermatol 2010; 3(2): 42-47.

  48. Schierle CF, Casas LA. “Nonsurgical rejuvenation of the aging face with injectable poly-L-lactic acid for restoration of soft tissue volume”. Aesthet Surg J 2011: 31(1): 95-109.

  49. Lowe NJ. “Optimizing poly-L-lactic acid use”. J Cosmet Laser Ther 2008; 10(1): 43-46.

  50. Lam SM, Azizzadeh B, Graivier M. “Injectable poly-L-lactic acid (Sculptra): technical considerations in soft-tissue contouring”. Plast Reconstr Surg 2006; 118(3 Suppl): 55S-63S.

  51. Narins RS. “Minimizing adverse events associated with poly-L-lactic acid injection”. Dermatol Surg 2008; 34 Suppl 1: S100-104.

  52. Jacovella PF. “Use of calcium hydroxylapatite (Radiesse) for facial augmentation”. Clin Interv Aging 2008; 3(1): 161-174.

  53. Vagefi MR, McMullan TF, Burroughs JR, White GL Jr, McCann Jd, Anderson RL. “Injectable calcium hydroxylapatite or orbital volume augmentation”. Arch Facial Plast Surg 2007; 9(6): 439-442.

  54. Godin MS, Majmundar MV, Chrzanowski DS, Dodson KM. “Use of Radiesse in combination with Restylane for facial augmentation”. Arch Facial Plast Surg 2006; 8(2): 92-97.

  55. Edelson KL. “Hand recontouring with calcium hydroxylapatite (Radiesse)”. J Cosmet Dermatol 2009; 8(1): 44-51.

  56. Bank DE. “A novel approach to treatment of the aging hand with Radiesse”. J Drugs Dermatol 2009; 8(12): 1122-1126.

  57. Sankar V. Mc Guff HS. “Foreign body reaction to calcium hydroxylapatite after lip augmentation”. J Am Dent Assoc 2007; 138(8): 1093-1096.

  58. Sires B, Laukaitis S, Whitehouse P. “Radiesse-induced herpes zoster”. Ophthal Plast Reconstr Surg 2008; 24(3): 218-219.

  59. Beer KR. “Radiesse nodule of the lips from a distant injection site: report of a case and consideration of etiology and management”. J Drugs Dermatol 2007; 6(8): 846-847.

  60. Alam M, Havey J, Pace N, Pongprutthipan M, Yoo S. “Large-particle calcium hydroxylapatite injection for correction of facial wrinkles and depressions”. J Am Acad Dermatol 2011; 65(1): 92-96.

  61. Jones DH. “Semipermanent and permanent injectable fillers”. Dermatol Clin 2009; 27(4): 433-444, vi.

  62. Lemperle G, Knapp TR, Sadick NS, Lemperle SM. “ArteFill permanent injectable for soft tissue augmentation: I. Mechanism of action and injection techniques”. Aesthetic Plast Surg. 2010; 34(3): 264-272.

  63. Lemperle G, Sadick NS, Knapp TR, Lemperle SM. “ArteFill permanent injectable for soft tissue augmentation: II. Indications and applications”. Aesthetic Plast Surg. 2010; 34(3): 273-286.

  64. Epstein RE, Spencer JM. “Correction of atrophic scars with ArteFill: an open-label pilot study”. J Drugs Dermatol 2010; 9(9): 1062-1064.

  65. Hilinski JM, Cohen SR. “Soft tissue augmentation with ArteFill”. Facial Plast Surg 2009; 25(2): 114-119.

  66. Sachdev M, Anantheswar Y, Ashok B, Hameed S, PAI SA. “Facial granulomas secondary to injection of semi-permanent cosmetic dermal filler containing acrylic hydrogel particles”. J. Cutan Aesthet Surg 2010; 3(3): 162-166.

  67. Bergeret-Galley C, Latouche X, Illouz YG. “The value of a new filler material in corrective and cosmetic surgery: DermaLive and Derma- Deep”. Aesthetic Plast Surg 2001; 25(4): 249-255.

  68. Rossner M, Rossner F, Bachmann F, Wiest L, Rzany B. “Risk of severe adverse reactions to an injectable filler based on a fixed combination of hydroxyethylmethacrylate and ethylmethacrylate with hyaluronic acid”. Dermatol Surg 2009; 35 Suppl 1: 367-374.

  69. Prather CL, Jones DH. “Liquid injectable silicone for soft tissue augmentation”. Dermatol Ther. 2006; 19(3): 159-168.

  70. Narins RS, Beer K. “Liquid injectable silicone: a review of its history, immunology, technical considerations, complications, and potential”. Plast Reconstr Surg 2006; 118(3 Suppl): 77S-84S.

  71. Cakmak O. Turkoz HK, Polat S, Serin GM, Hizal E. Tanveri H. “Histopathologic response to highly purified liquid silicone injected intradermally in rats skin”. Aesthetic Plast Surg 2011; 35(4): 538-544.

  72. James SJ, Pogribna M. Miller BH, Bolon B. Muskhelishvili L. “Characterization of cellular response to silicone implants in rats: implications for foreign-body carcinogenesis”. Biomaterials 1997; 18(9): 667-675.

  73. Jacinto SS. “Ten-year experience using injectable silicone oil for soft tissue augmentation in the Philippines”. Dermatol Surg 2005; 31(11 Pt 2): 1550-1554; discussion 1554.

  74. Barnett JG, Barnett CR. “Treatment of acne scars with liquid silicone injections: 30-year perspective”. Dermatol Surg 2005; 31(11 Pt 2): 1542- 1549.

  75. Duffy DM. “Silicone: A critical review”. Adv. Dermatol 199; 5: 93-107.

  76. Gómez de la Fuente E, Álvarez-Fernández JG, Naz E, Gamo R, Pinedo F, Vincente Martín FJ, et al. “Cutaneous adverse reaction to Bio-Alcamid implant”. Actas Dermatosifiliogr 2007; 98(4): 271-275.

  77. Karim RB, Hage JJ, Van Rozelaar L, Lange CA, Raaijmakers J. “Complications of polyalkylimide 4% injections (Bio-Alcamid): a report of 18 cases”. J Plast Reconstr Aesthet Surg 2006; 59(12): 1409-1414.

  78. Alijotas-Reig J, Miró-Mur F, Planells-Romeu I, García-Aranda N, Garcia- Gimenez V, Viladerdell-Tarrés M. “Are bacterial growth and/or chemotaxis increased by filler injections? Implications for the pathogenesis and treatment of filler-related granulomas”. Dermatology 2010; 221(4): 356-364.

  79. Ross AH, Malhotra R. “Long-term orbitofacial complications of polyalkylimide 4% (bio-alcamid)”. Ophtal Plast Reconstr Surg 2009; 25(5): 394-397.

  80. Schelke LW, Van den Elzen HJ, Canninga M, Neumann MH. “Complications after treatment with polyalkylimide”. Dermatol Surg 2009; 35 Suppl 2: 1625-1628.

  81. Wolters M, Lampe H. “Prospective multicenter study for evaluation of safety, efficacy, and esthetic results of cross-linked polyacrylamide hydrogel in 81 patients”. Dermatol Surg 2009; 35(1): 338-343.

  82. Rauso R, Gherardini G, Parlato V, Amore R, Tartaro G. “Polyacrylamide Gel for Facial Wasting Rehabilitation: How Many Milliliters per Session?”. Aesthetic Plast Surg 2011, Epub ahead.

  83. von Buelow S, Pallua N. “Efficacy and Safety of Polyacrylamide Hydrogel for Facial Soft-Tissue Augmentation in a 2-Year Follow-Up: A Prospective Multicenter Study for Evaluation of Safety and Aesthetic Results in 101 Patients”. Plastic & Reconstructive Surgery 2006; 118(3S): 85S-91S.

  84. Ono S, Ogawa R, Hyakusoku H. “Complications after polyacrylamide hydrogel injection for soft-tissue augmentation”. Plast Reconstr Surg 2010; 126(4): 1349-1357.

  85. Pallua N, Wolter TP. “A 5-year assessment of safety and aesthetic results after facial soft-tissue augmentation with polyacrylamide hydrogel (Aquamid): a prospective multicenter study of 251 patients”. Plast Reconstr Surg 2010; 125(6): 1797-804.




2020     |     www.medigraphic.com